Aspirin a Day Could Dramatically Cut Cancer Risk, Says Biggest Study Yet

August 6th, 2014

There are some risks, but even considering those… It makes for an interesting read at a minimum.

Via: Guardian:

An aspirin a day could dramatically cut people’s chances of getting and dying from common cancers, according to the most detailed review yet of the cheap drug’s ability to stem disease.

More than 130,000 deaths would be avoided over a 20-year period if Britain’s 50- to 64-year-olds took a daily aspirin for 10 years, because the beneficial effects continue even when the aspirin is stopped, the authors say.

A research team led by Professor Jack Cuzick, head of the centre for cancer prevention at Queen Mary University of London, concluded that people between 50 and 65 should consider regularly taking the 75mg low-dosage tablets.

Cuzick said that taking aspirin “looks to be the most important thing we can do to reduce cancer after stopping smoking and reducing obesity, and will probably be much easier to implement”.

Posted in Health | Top Of Page

5 Responses to “Aspirin a Day Could Dramatically Cut Cancer Risk, Says Biggest Study Yet”

  1. Dennis Says:

    And if that doesn’t work, another one from the medicine cabinet that could be helpful is Mebendazole…Worm pills.

  2. mangrove Says:

    Bayer and Death: 1918 and Aspirin

  3. tal Says:

    Surely it’s just coincidence this emerges just 2 months after FDA pulled the heart-attack-prevention recommendation:

    Limit Use of Aspirin to Prevent Heart Attack, FDA Says
    Aspirin didn’t help prevent heart attacks or strokes in people with a high risk of heart disease yet don’t show any symptoms, according to a Scottish study published in the Journal of the American Medical Association in 2010. Higher-risk people had a similar number of attacks and strokes as participants taking placebo, the researchers said.

  4. erth2karin Says:

    So, after reading the Guardian article and mangrove’s link it looks like the choice is lower cancer risk vs debilitated immune system. But a damaged immune system is a welcome mat for cancer, so it appears that they’re trying to A) Increase sales of aspirin via cancerphobic westerners; B) Depress people’s immune systems, giving them a larger market for pharmeceuticals (and possibly simultaneously dercreasing the surplus population); and C) Not actually lower cancer rates at all.
    Win-win-win!! :/

  5. tal Says:

    More info:

    The first thing I check in any article is declarations of interest. If someone tells me walnuts are going to save lives and they and/or the study were funded by the walnut foundation, I am inclined not to take much of what I read very seriously.

    In this article the disclosure states: “JC [that’s the lead author – the one who was on the TV that day]: Member of the Bayer advisory board. JB: Consultancy for Bayer Pharma. Research funding from Bayer Pharma. A stockholder and medical director in QuantuMDx, a new medical devices company which will develop point of care pharmacogenetic testing. Aspirin sensitivity is one of company’s targets. JAJ: Consultant to Astra-Zeneca, Dr Falk Pharmaceuticals, Chief investigator of AspECT trial and ChoPIN trial. PMR: Has received honoraria for talks, advisory boards and clinical trial committees from several pharmaceutical companies with an interest in antiplatelet agents including Astra-Zeneca, Bayer, Boehringer Ingelheim, Sanofi-BMS, Biotronic, Johnson & Johnson and Servier, and is on the executive committee of the ARRIVE trial. Research funding from Boehringer Ingelheim. All remaining authors have declared no conflicts of interest.”

Leave a Reply

You must be logged in to post a comment.